Therefore, our study aims to determine the physiological and pathophysiological distribution of the radiopharmaceutical Ga68-PSMA-617 by detecting the range of uptake in the organs and tissues, primary prostate tumor, lymph node, and bone metastasis and investigate whether there are differences in distribution according to the laboratory, histopathological and clinical findings that can affect image evaluation of Ga68-PSMA-617 PET/CT in prostate cancer patients. Here, FOLH1 is linked to prostate carcinoma.